Navigation Links
Cepheid Welcomes Senior Vice President of Human Resources
Date:1/17/2012

SUNNYVALE, Calif., Jan. 17, 2012 /PRNewswire/ -- Cepheid (Nasdaq: CPHD) today announced that it has appointed Mr. Mike Fitzgerald to the position of Senior Vice President, Human Resources, effective January 14, 2012. 

Mr. Fitzgerald joins Cepheid from Verigy, Inc., a wholly owned subsidiary of Advantest Corp., where he most recently served as Senior Vice President of Human Resources.  Prior to Verigy, Mr. Fitzgerald was Vice President of Human Resources at Varian, Inc. where he was responsible for the development and implementation of a global human resources program in support of the company's corporate goals for approximately 3,500 employees worldwide.  In total, Mr. Fitzgerald brings more than two decades of broad human resources experience to Cepheid, including Vodafone, PLC, and Xerox Financial Services.

In connection with his employment, the Compensation Committee of Cepheid's Board of Directors has granted Mr. Fitzgerald an option to purchase 56,000 shares of Cepheid common stock at the closing price of Cepheid common stock on Mr. Fitzgerald's employment commencement date and restricted stock units in respect of 10,000 shares of Cepheid common stock.  The option will become exercisable by Mr. Fitzgerald over four years, with 25% vesting on the one-year anniversary of grant and ratably monthly thereafter, and will expire after seven years from the grant date, so long as Mr. Fitzgerald continues to be employed or provide services to Cepheid.  The restricted stock units will become exercisable by Mr. Fitzgerald over four years, with 25% vesting on the one-year anniversary of the grant and as to an additional 1/16th of the restricted stock units at the end of each three-month period thereafter, so long as Mr. Fitzgerald continues to be employed or provide services to Cepheid.  The option and restricted stock units were granted as inducement grants pursuant to Section 5635(c)(4) of The NASDAQ Stock Market Rules.

About CepheidBased in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests.  By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases.  Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit http://www.cepheid.com.

CONTACTS:For Media Inquiries:For Investor Inquiries:Jared Tipton

Jacquie RossCepheid Corporate Communications

Cepheid Investor RelationsTel: (408) 400 8377

Tel: (408) 400 8329cepheid.com%7Cinvestor.relations@cepheid.com" target="_blank">jared.tipton@cepheid.com

investor.relations@cepheid.com


'/>"/>

SOURCE Cepheid
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Cepheid Receives FDA Clearance for Xpert Flu, Delivering Simultaneous Detection and Differentiation of Flu A, Flu B, and 2009 H1N1 Strain
2. Cepheid Schedules 2010 Third Quarter Financial Results Announcement and Webcast
3. Cepheid to Webcast Upcoming Financial Presentations
4. Cepheid Expands Leadership Team With Appointment of Executive Vice President of Worldwide Commercial Operations
5. Cepheid Schedules 2009 Third Quarter Financial Results Announcement and Webcast
6. Cepheid Schedules 2009 Second Quarter Financial Results Announcement and Webcast
7. Cepheid Announces Symposium Speakers and Program Highlights for 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
8. Cepheid Reports 2009 First Quarter Results
9. Cepheid Schedules Fiscal 2009 First Quarter Financial Results Announcement and Webcast
10. Cepheid Announces New Diagnostic Technology to Aid World Efforts in Halting the Spread of Mycobacterium Tuberculosis (TB)
11. Cepheid Announces Preliminary 2008 Fourth Quarter and Full Year Revenue Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... Feb. 16, 2017 Research and ... Biology: Global Markets" report to their offering. ... ... genes, biobrick parts, delivery plasmids, chassis organisms, synthetic cells, ... assembly, genome editing, bioinformatics and specialty media) and enabled ...
(Date:2/16/2017)... HOLLISTON, Mass. , Feb. 16, 2017   ... or the "Company"), a biotechnology company developing bioengineered organ ... the esophagus, bronchus and trachea, announced today the closing ... offering of 20,000,000 shares of common stock and warrants ... gross proceeds of $8.0 million. The offering was priced ...
(Date:2/16/2017)... , Feb. 16, 2017 UCHealth ( ... utilize LungDirect for pulmonary nodule patient management. In addition ... or a spot on the lung, UCHealth looks to ... manual data entry. Stephanie Brown, RN ... my nodule patients with an Excel spreadsheet, which was ...
(Date:2/16/2017)... 2017  Champions Oncology, Inc. (NASDAQ: CSBR ... of advanced technology solutions and products to personalize the ... addition of new cohorts of PDX models to their ... expand Champions, product line in hepatocellular cancer, breast cancer, ... and non-small cell lung cancer (including EGFR mutation; ALK/ROS1 ...
Breaking Biology Technology:
(Date:2/7/2017)... , February 7, 2017 Ipsidy ... Solutions Corporation [OTC: IDGS], ("Ipsidy" or the "Company") a ... transaction processing services, is pleased to announce the following ... Effective January 31, 2017, Philip D. ... Directors, CEO and President.  An experienced payment industry professional ...
(Date:2/3/2017)... 2017  Texas Biomedical Research Institute announced that its Board ... as the Institute,s new President and CEO. Dr. Schlesinger ... 2017. He is currently the Chair of the Department of ... Microbial Interface Biology at Ohio State University. "We ... and CEO of Texas Biomed," said Dr. James O. ...
(Date:2/2/2017)... JACKSONVILLE, Fla. , Feb. 2, 2017 /PRNewswire/ ... ), a clinical-stage immuno-oncology company specializing in the ... vaccines for the treatment of cancer and metastatic ... multi-gram scale-up and GMP manufacturing of a second ... T-cell vaccine targeting folate receptor alpha. The manufactured ...
Breaking Biology News(10 mins):